Explore Trevogrumab dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Trevogrumab is an experimental anti-myostatin monoclonal antibody (a large protein, not a small peptide) once studied for muscle-wasting. It ships as a lyophilized powder you reconstitute, and genuine antibody is hard to source, so what arrives under this name should be treated with caution.
High-affinity, selective neutralisation of circulating mature GDF-8 dimer, preventing ligand binding to ActRIIB/ActRIIA and blocking downstream Smad2/3 signalling in skeletal muscle. Selectivity over the closely related ligand GDF-11 was a deliberate design choice intended to avoid off-target effects on cardiac and neural tissues where GDF-11 has been implicated in age-related biology.[2]
No regulatory approvals. Investigated in Phase 1/2 trials for sarcopenia in older adults and (in combination with garetosmab and an ActRIIB-Fc, REGN2477) for Duchenne muscular dystrophy. The sarcopenia programme was discontinued after Phase 2 readout.[1] **Typical dose:** Trevogrumab is not commercially available outside of trial settings; published Phase 1/2 trials used 1–30 mg/kg intravenous monthly dosing. There is no validated dose for non-trial use.[1][2]
Regeneron monoclonal antibody. Phase 2 sarcopenia programme discontinued; no approval.
Trevogrumab has a reported half-life of ~3 weeks. The pharmacokinetic reference models an interval of about once every 4 weeks; this is not a measured community cadence or a dosing recommendation. As a monoclonal antibody, trevogrumab has a multi-week half-life and accumulates over the first couple of months of dosing before reaching steady state. Pharmacokinetic source: Clinical PK for the anti-myostatin antibody (REGN1033). It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough Trevogrumab calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.